With investors looking for safety and dividends for total return, the big pharmaceutical stocks are just the ticket, and these four are outstanding.
February 26, 2016: Markets opened higher on Friday on rising oil prices in Asia and Europe which turned into lower prices as the trading day went along. Basic materials and financials were…
For the long haul, these three stock should provide a much better avenue for total return and continue to increase dividend payouts.
The February 12 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
The most shorted stock traded on the New York Stock Exchange — Chesapeake Energy — bucked the short interest trend with a modest gain in February.
Pfizer has announced that the FDA approved Xeljanz XR (tofacitinib citrate) extended-release tablets for the once-daily treatment of moderate to severe rheumatoid arthritis in certain patients.
Chris Lange These stocks make good sense for long-term patient investors that have a growth and income total return bias in their portfolios.
In a new research report, Jefferies shuffles some of the pharmaceutical stocks in its coverage universe and a beaten-down dividend leader is now the top pick globally.
For worried investors that need an income stream, all these top stocks make good sense for growth and income portfolios.
Pfizer has announced that it had settled outstanding claims for a total of more than $784 million related to calculated Medicaid rebates for the drug Protonix.
Paul Ausick Here are six biotech and pharma stocks that analysts are telling their firm's clients to buy now for solid upside opportunities ahead.
The January 29 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
Among the six most heavily shorted stocks traded on the New York Stock Exchange, short sellers continued to pile on Alcoa and Freeport-McMoRan between the January 15 and January 29 settlement dates.
Merrill Lynch has decided to add Pfizer as its new top pick for 2016. The firm reiterated a Buy rating with a $39 price target.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Apple, Freeport-McMoRan, Kinross Gold, Pfizer, Plains All American, Salesforce,com, Tesla and Yelp.
